UNLABELLED: The type 1 cannabinoid receptor (CB1) is a crucial modulator of synaptic transmission in the brain. Animal and postmortem human data suggest that mutant huntingtin represses CB1 transcription. Our aim was to measure CB1 levels in the brains of Huntington disease (HD) patients in vivo. METHODS: Twenty symptomatic HD patients and 14 healthy controls underwent PET with the novel CB1 ligand N-[2-(3-cyano-phenyl)-3-(4-(2-(18)F-fluorethoxy)phenyl)-1-methylpropyl]-2-(5-methyl-2-pyridyloxy)-2-methylproponamide. RESULTS: We observed a profound decrease of CB1 availability throughout the gray matter of the cerebrum, cerebellum, and brain stem in HD patients, even in early disease stages. Disease burden ([number of CAG repeats in the HTT gene - 35.5] x age) was inversely correlated with CB1 availability in the prefrontal and premotor cortex. CONCLUSION: The profound early and widespread reduction of CB1 availability in vivo is consistent with the hypothesis that mutant huntingtin represses CB1 transcription. This is the first, to our knowledge, in vivo demonstration of disturbance of the endocannabinoid system in a human neurologic disease.
UNLABELLED: The type 1 cannabinoid receptor (CB1) is a crucial modulator of synaptic transmission in the brain. Animal and postmortem human data suggest that mutant huntingtin represses CB1 transcription. Our aim was to measure CB1 levels in the brains of Huntington disease (HD) patients in vivo. METHODS: Twenty symptomatic HDpatients and 14 healthy controls underwent PET with the novel CB1 ligand N-[2-(3-cyano-phenyl)-3-(4-(2-(18)F-fluorethoxy)phenyl)-1-methylpropyl]-2-(5-methyl-2-pyridyloxy)-2-methylproponamide. RESULTS: We observed a profound decrease of CB1 availability throughout the gray matter of the cerebrum, cerebellum, and brain stem in HDpatients, even in early disease stages. Disease burden ([number of CAG repeats in the HTT gene - 35.5] x age) was inversely correlated with CB1 availability in the prefrontal and premotor cortex. CONCLUSION: The profound early and widespread reduction of CB1 availability in vivo is consistent with the hypothesis that mutant huntingtin represses CB1 transcription. This is the first, to our knowledge, in vivo demonstration of disturbance of the endocannabinoid system in a humanneurologic disease.
Authors: Eric A Horne; Jonathan Coy; Katie Swinney; Susan Fung; Allison E T Cherry; William R Marrs; Alipi V Naydenov; Yi Hsing Lin; Xiaocui Sun; C Dirk Keene; Eric Grouzmann; Paul Muchowski; Gillian P Bates; Ken Mackie; Nephi Stella Journal: Eur J Neurosci Date: 2012-11-21 Impact factor: 3.386
Authors: Jose Luis López-Sendón Moreno; Juan García Caldentey; Patricia Trigo Cubillo; Carolina Ruiz Romero; Guillermo García Ribas; M A Alonso Alonso Arias; María Jesús García de Yébenes; Rosa María Tolón; Ismael Galve-Roperh; Onintza Sagredo; Sara Valdeolivas; Eva Resel; Silvia Ortega-Gutierrez; María Laura García-Bermejo; Javier Fernández Ruiz; Manuel Guzmán; Justo García de Yébenes Prous Journal: J Neurol Date: 2016-05-09 Impact factor: 4.849
Authors: Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra Journal: Medchemcomm Date: 2019-03-18 Impact factor: 3.597
Authors: Javier Fernández-Ruiz; Miguel Moreno-Martet; Carmen Rodríguez-Cueto; Cristina Palomo-Garo; María Gómez-Cañas; Sara Valdeolivas; Carmen Guaza; Julián Romero; Manuel Guzmán; Raphael Mechoulam; José A Ramos Journal: Br J Pharmacol Date: 2011-08 Impact factor: 8.739